financetom
Business
financetom
/
Business
/
Indian Edtech Consortium aims to protect consumer interest: upGrad MD
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Indian Edtech Consortium aims to protect consumer interest: upGrad MD
Jan 20, 2022 1:57 PM

If one has to pick the biggest startup success story of the pandemic - it would have to be edtech sector. From being a medium of choice, remote learning or learning anything anywhere suddenly went mainstream as all stakeholders switched to digital.

In fact, four out of the six Indian edtech unicorns, achieved their billion dollar valuations just in the last 12 months, a testimony to the kind of boom witnessed by the Indian edtech sector.

A Praxis-IVCA report pegged the education market at USD 117 billion in 2020 with 360 million learners and expected to grow 2x to USD 225 billion by FY25 a CAGR of 14 percent over FY20-25.

But as they say with great power comes great responsibility! So while the success has been stupendous, controversies have followed as well - from mis-selling, to overly aggressive sales tactics and misleading advertising, flags have been raised on how this hyper competitive segment has been going about growing its business.

In a bid to bring in self-regulation, edtech companies have now formed the Indian Edtech Consortium.

The consortium will work under a common 'code of conduct' and establish a two-tier grievance redressal mechanism.

This move to self-regulate also follows growing concerns of the government which led to the education ministry issuing an advisory to parents and cautioning them against possible violations.

So how will this consortium regulate itself, how can these companies work with each other and institutions to improve the learning landscape to build a quality education system that is equal and fair for all? To discuss this CNBC-TV18 spoke to Mayank Kumar, Co-founder & MD of upGrad; Tanushree Nagori, Co-founder of Doubtnut and Akshay Chaturvedi, Founder & CEO of Leverage Edu.

Watch video for more.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
K-Bro Linen Maintained at Buy at Stifel GMP Following a Tuck-In Acquisition; Price Target Kept at C$45.00
K-Bro Linen Maintained at Buy at Stifel GMP Following a Tuck-In Acquisition; Price Target Kept at C$45.00
Jun 24, 2024
09:36 AM EDT, 06/24/2024 (MT Newswires) -- Stifel GMP on Monday reiterated its buy rating on the shares of K-Bro Linen ( KBRLF ) and its C$45.00 price target after the company last week closed a small acquisition of a Montreal rival. K-Bro announced the acquisition of Buanderie C.M., a healthcare laundry and linen operator in North Montreal, for $12mm...
America Movil Increases Stake in ClaroVTR to 91%
America Movil Increases Stake in ClaroVTR to 91%
Jun 24, 2024
09:48 AM EDT, 06/24/2024 (MT Newswires) -- America Movil ( AMX ) said Monday it has increased its stake in ClaroVTR, its joint venture with Liberty Latin America, to 91%. The company said it increased its ownership by converting its outstanding notes held in ClaroVTR into equity. Financial terms of the increase weren't disclosed. Liberty Latin America will own the...
VCI Global to Invest $30 Million in TalkingData Group Holding
VCI Global to Invest $30 Million in TalkingData Group Holding
Jun 24, 2024
09:45 AM EDT, 06/24/2024 (MT Newswires) -- VCI Global ( VCIG ) said Monday that it signed an agreement to invest up to $30 million in TalkingData Group Holding, which provides big data analytics and artificial intelligence-powered solutions in Asia. The investment will make VCI Global ( VCIG ) a substantial shareholder of TalkingData Group and grant VCI Global (...
Alnylam's Closely Watched Phase 3 Heart Disease Trial Of Vutrisiran Hits Primary Endpoint, Shares Surge
Alnylam's Closely Watched Phase 3 Heart Disease Trial Of Vutrisiran Hits Primary Endpoint, Shares Surge
Jun 24, 2024
Monday, Alnylam Pharmaceuticals Inc ( ALNY ) revealed topline results from its HELIOS-B Phase 3 study of vutrisiran, an investigational RNAi therapeutic in development for ATTR amyloidosis with cardiomyopathy (ATTR-CM). ATTR-CM is a type of heart muscle disease that occurs when amyloid fibrils – clumps of misfolded proteins – are deposited into heart tissue and cause it to stiffen. Also...
Copyright 2023-2026 - www.financetom.com All Rights Reserved